Reimagining Renal Cell Carcinoma Therapy: Bridging Conventional Gaps with Monoclonal Antibodies (mAbs), Tyrosine Kinase Inhibitors (nibs), and Nanocarriers.

Renal cell carcinoma (RCC), a highly aggressive kidney malignancy, presents significant challenges in early diagnosis, therapeutic resistance, and metastatic progression. Conventional treatment modalities, including surgery, radiotherapy, and chemotherapy, remain essential but are often limited by non-specific toxicity, resistance development, and suboptimal long-term outcomes in advanced stages. In response, molecular-targeted therapies, such as monoclonal antibodies (mAbs) and tyrosine kinase inhibitors, have significantly improved RCC management by selectively disrupting key signaling pathways, including vascular endothelial growth factor (VEGF), plateletderived growth factor (PDGF), and mammalian target of rapamycin (mTOR). However, these therapies still have limitations, including transient responses and systemic adverse effects. Emerging technologies represent promising approaches. Notably, circulating tumor cells (CTCs) are recognized as critical biomarkers in the metastatic cascade, enabling real-time disease monitoring through liquid biopsy. Concurrently, nanotechnology-based platforms, including lipidic and polymeric nanoparticles, have enabled precision drug delivery with enhanced therapeutic efficacy and reduced toxicity. Drug carriers such as liposomes, solid-lipid nanoparticles, and PLGA-based systems successfully deliver chemotherapeutics, siRNAs, and natural compounds targeting key oncogenic pathways, including PI3K-AKT-mTOR (phosphoinositide 3-kinase-protein kinase B (AKT)- mTOR) and VHL-HIF (von Hippel-Lindau tumor suppressor-hypoxia-inducible factor) signaling. Furthermore, multifunctional theranostic platforms integrate diagnostic imaging and therapeutic functions, advancing personalized treatment strategies. Collectively, these innovations represent a paradigm shift from conventional broad-spectrum treatments to intelligent, patient-specific approaches, with the potential to redefine RCC management and improve clinical outcomes.